MDT

86.16

+0.34%↑

114.56

-0.5%↓

VEEV

172.73

-1.38%↓

HQY

83.08

+0.23%↑

PHR.US

8.18

-2.5%↓

MDT

86.16

+0.34%↑

114.56

-0.5%↓

VEEV

172.73

-1.38%↓

HQY

83.08

+0.23%↑

PHR.US

8.18

-2.5%↓

MDT

86.16

+0.34%↑

114.56

-0.5%↓

VEEV

172.73

-1.38%↓

HQY

83.08

+0.23%↑

PHR.US

8.18

-2.5%↓

MDT

86.16

+0.34%↑

114.56

-0.5%↓

VEEV

172.73

-1.38%↓

HQY

83.08

+0.23%↑

PHR.US

8.18

-2.5%↓

MDT

86.16

+0.34%↑

114.56

-0.5%↓

VEEV

172.73

-1.38%↓

HQY

83.08

+0.23%↑

PHR.US

8.18

-2.5%↓

Home・Aandelen Lijst・Kura Oncology Inc

Kura Oncology Inc

Open

SectorGezondheidszorg

8.67 2.6

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

7.73

Max

8.69

Belangrijke statistieken
By Trading Economics
Inkomsten	-6.9M -81M
Verkoop	-3.4M 17M
Winstmarge	-467.23
Werknemers	260
EBITDA	-12M -86M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+241.33% upside

Dividenden
By Dow Jones
Volgende Winsten	30 apr 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-73M 683M
Vorige openingsprijs	6.07
Vorige sluitingsprijs	8.67

Nieuwssentiment

By Acuity

50%

163 / 349 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

5.575 / 6.6 Steun & Weerstand

Kura Oncology Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 apr 2026, 22:56 UTC

Belangrijke Nieuwsgebeurtenissen

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

1 apr 2026, 20:50 UTC

Acquisities, Fusies, Overnames

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

1 apr 2026, 23:55 UTC

Marktinformatie

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

1 apr 2026, 23:43 UTC

Marktinformatie

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

1 apr 2026, 23:23 UTC

Belangrijke Nieuwsgebeurtenissen

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

1 apr 2026, 23:07 UTC

Winsten

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

1 apr 2026, 23:02 UTC

Belangrijke Nieuwsgebeurtenissen

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

1 apr 2026, 23:00 UTC

Belangrijke Nieuwsgebeurtenissen

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

1 apr 2026, 23:00 UTC

Belangrijke Nieuwsgebeurtenissen

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

1 apr 2026, 23:00 UTC

Belangrijke Nieuwsgebeurtenissen

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

1 apr 2026, 22:39 UTC

Winsten

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

1 apr 2026, 22:08 UTC

Marktinformatie

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

1 apr 2026, 21:56 UTC

Acquisities, Fusies, Overnames

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

1 apr 2026, 21:31 UTC

Belangrijke Nieuwsgebeurtenissen

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

1 apr 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

1 apr 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

1 apr 2026, 20:38 UTC

Winsten

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

1 apr 2026, 20:31 UTC

Acquisities, Fusies, Overnames

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

1 apr 2026, 20:16 UTC

Acquisities, Fusies, Overnames

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

1 apr 2026, 20:16 UTC

Acquisities, Fusies, Overnames

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

1 apr 2026, 20:13 UTC

Acquisities, Fusies, Overnames

Gilead Extends Tender Offer To Acquire Arcellx >GILD

1 apr 2026, 20:07 UTC

Marktinformatie

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

1 apr 2026, 20:07 UTC

Acquisities, Fusies, Overnames

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Peer Vergelijking

Prijswijziging

Kura Oncology Inc Prognose

Koersdoel

By TipRanks

241.33% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 27.75 USD 241.33%

Hoogste 40 USD

Laagste 15 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kura Oncology Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Kura Oncology Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.575 / 6.6Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

163 / 349 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.